Surf Bio Announces $16 Million Series Seed Financing
PRIVATEApr 12, 2022
Amount Raised
$16 Million
Round Type
Seed
Palo Alto
Description
Surf Bio, Inc., a biopharmaceutical company commercializing a novel drug stabilization platform, today announced a $16 million Series Seed round of funding. The financing was co-led by Breakout Ventures and the Perceptive Xontogeny Venture Fund (“PXV Fund”). The company will use the funds to advance its polymer-based drug delivery platform and accelerate the development of an ultra-rapid insulin for treatment of diabetes.
Who to call at Surf Bio, and when
A new round usually means Surf Bio is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Surf Bio raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Surf Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Surf Bio. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Surf Bio
Location
Palo Alto, California, United States
About
Surf Bio is a preclinical biopharmaceutical company leveraging a novel biotechnology platform to develop enhanced therapeutic solutions for diabetes, oncology, infectious diseases, gene therapy, and other therapeutic areas. Surf Bio was launched by the founders of Bigfoot Biomedical and Mode AGC to commercialize a breakthrough drug stabilization technology developed in the Appel Lab. Commercially, the technology is designed to enable reduction of refrigeration requirements, transition from IV to subcutaneous therapy, and novel pharmaceutical formulations across a range of therapeutic areas. For more information about Surf Bio, visit www.surf.bio.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Surf Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Palo Alto